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in Solid Organ Transplantation
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A b s t r A c t
Patients with end-stage organ diseases, as well as solid organ transplantation recipi-
ents have reduced immune response to many vaccines. Thus, vaccination should be 
performed as early as possible during the natural course of their primary disease. 
Verifying immunization status and updating vaccinations are important steps in the 
evaluation of patients who are on a waiting list for solid organ transplantation. Poten-
tial benefits of vaccination outweigh the vaccine-related adverse events. According 
to current literature, there is no association between rejection episodes and previ-
ous exposure to vaccination. Furthermore, several viral infections have been reported 
to trigger graft rejection. This suggests that infectious agents, more commonly than 
vaccines, are a cause of graft rejection episodes, and effective immunization may be 
protective. Current information on vaccination for adult solid organ transplant candi-
dates is reviewed in this article.
I N t r O D U c t I O N
Clinical course and survival of patients after solid organ transplantation have 
greatly improved over the last 20 years. Consequently, novel preventive and effective 
health measures are needed for the maintenance of the general health, not only for 
this fragile and vulnerable group of patients, but also for the community which is the 
source of solid organ grafts.1 Anti-rejective immunosuppressive treatments expose 
these patients to a higher risk of life-threatening infections. At the same time, antimi-
crobial agents often exhibit poorer effectiveness in comparison to the one observed 
in the immunocompetent.2 Therefore, prevention of infections in these patients is of 
fundamental importance.
Vaccinations can prevent diseases and reduce the proliferation and spread of vari-
ous infectious agents. Nevertheless, even if active immunization is the key mechanism 
to preventing infections, many solid organ transplant recipients, who are under long-
term immunosuppressive treatment, cannot achieve protective immune response even 
after the execution of a complete vaccination timetable. Moreover, vaccination with 
live attenuated vaccines carries with it the risk of an uncontrolled proliferation of the 
strain included in the vaccine and consequently such vaccination is avoided in solid 
organ transplant recipients.
It is important to clearly distinguish the documented contraindications for the 
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administration of a vaccine derived from strong clinical or bib-
liographic data, from those warnings emanating from mainly 
theoretical interpretations and sometimes personal thoughts 
of some clinicians. Not infrequently, the decision to offer a 
vaccine should be supported by the balance between two fac-
tors; first, the benefit, resulting from vaccination, following 
the prevention of an infectious disease and second the adverse 
effects or the risk of developing a life-threatening infection, 
from the wild strain of the pathogenic microorganism that may 
be contained in the vaccine.3
The risk of the development of an infectious disease and 
the failure to prevent it by active immunization is directly 
related to the immune competence of each patient. The great-
est the degree of the therapeutic immunosuppression, the 
less possible to obtain an adequate response following active 
immunization. Recipients of solid organs, at least for the first 
two months after transplantation, are among the individuals 
with severe immunosuppression.3 Factors that contribute to the 
negative modification of the recipient’s immune competency 
include underlying diseases, e.g., renal or hepatic insufficiency, 
a history of allograft rejection episode and the type of im-
munosuppressive therapy administered after transplantation.
A number of reasonable questions arise in clinical practice 
for transplanted individuals, concerning a) the effect of im-
munosuppression during vaccination exposure before trans-
plantation, b) the efficacy of vaccinations after transplantation, 
c) the side effects of vaccines that contain live or inactivated 
strains in immunocompromised patients, and d) the effect of 
the vaccines on grafts function.4
G e N e r A L  P r I N c I P L e s
Candidates for solid organ transplantation demonstrate 
an increased risk of infective complications. A variety of these 
transmissible complications can be effectively prevented if the 
appropriate vaccination schedule is carried out prior to trans-
plantation. Therefore, an urgent need is emerging for health 
authorities before performing a transplantation; they should 
certify that the full timetable of planned vaccinations has been 
executed with respect to the transplantation candidate, his/
her relatives and those health care professionals who support 
him/her (Table 1).
For example, the response to vaccination of patients with 
end-stage renal and/or liver disease is poor, while the one 
applied to solid organ transplant recipients is even poorer, 
in comparison to the one detected in healthy individuals. In 
addition, several studies reported that patients with organ 
failure and/or solid organ transplantation exhibit a faster 
reduction of serum antibody response titles after vaccination. 
The decrease of immune response in persons with underly-
ing terminal illness was the fact that led to the modification 
of hepatitis B vaccine preparations available in the market, 
pointing to the group of patients with end-stage renal disease 
under hemodialysis (Recombivax HB, 40 mg, 3 doses at 0, 1 
and 6 months; and Engerix-B, 40 mg, 4 doses at 0, 1, 2, and 6 
months). Nevertheless, published studies present data where 
solid organ transplant recipients exhibited cellular immune 
response after a completed vaccination schedule, comparable 
to the response observed in the control groups.5
tAbLe 1. Vaccinations in Patients with Solid Organ Transplantation.7
vaccine recommendations 
BCG Contraindicated
Diphtheria, Tetanus, Pertussis Before and after transplantation
Haemophilus influenzae Before and after transplantation
Hepatitis A For travelers to endemic areas before and after transplantation
Hepatitis B Before and after transplantation
Influenza Patients and family members before and after transplantation
MMR Before transplantation
Pneumococcal Before and after transplantation
Polio (oral) Contraindicated
Vaccinia Contraindicated in patients, household members, transplant health-care workers
Varicella Controversial
Yellow Fever Contraindicated
BCG= Bacillus Calmette-Guérin, MMR= Measles, Mumps, Rubella vaccine
80
HOSPITAL CHRONICLES 10(2), 2015
Vaccination requirements for solid organ transplant 
candidates should be documented during patients’ initial as-
sessment and vaccination coverage must be completed before 
their inclusion in the transplant register. Indeed, in many organ 
transplant centres serological testing for infections that can 
be prevented by vaccination is routinely performed, including 
hepatitis B, chickenpox, measles, mumps and rubella with the 
goal to provide individualized recommendations to each ap-
plicant before transplantation.
It is generally accepted that due to the therapeutic immu-
nosuppression received by solid organ transplant recipients, 
their immune system is unable to respond effectively. Most 
immunosuppressive regimens used in this group of patients 
include combinations of steroids and calcineurin inhibitors 
such as cyclosporine and tacrolimus. Consequently, both 
T- and B-cells’ response is disturbed, firstly because of the 
inhibition of their proliferation, which is normally induced by 
antigen stimulation and secondly as a result of the interruption 
of cytokine production after such a stimulation.
Corticosteroids are potent cytokine inhibitors (interleukin 
1, 2, 6, tumor necrosis factor and interferon gamma) and T-cell 
proliferation blockers. However, the degree of immunosup-
pression achieved merely by taking steroids, does not seem 
to fully disrupt immune response after the administration of 
a vaccine.
Calcineurin inhibitors directly inhibit T-cell proliferation 
induced by interleukin 2, while halting the production of 
interleukin 4 and 5 from T-cells, that subsequently have an 
inhibitory effect on B-cell activity and antibody production. 
Azathioprine and mycophenolate mofetil, which are used as 
third line immunosuppressive agents, interfere with purine 
synthesis, whereas they inhibit T- and B-cell proliferation at 
different stages.4
However, the above figures of immunosuppressive inter-
ventions are often supplemented by the co-administration of 
the recombinant humanized (daclizumab) or the chimeric 
(basiliximab) monoclonal antibodies (IgG1), which exhibit 
their activity without destroying activated T-lymphocytes, or 
by the co-administration of antibodies such as monoclonal 
antibody OKT-3 or antithymocyte globulin (ATG) with de-
structive effect on T-cells and in case of rituximab on B-cells.6
The combination of these mechanisms leads to the sig-
nificant disturbance of the metabolic cascade resulting from 
the presentation of an antigen to the immune system cells. 
However, it is not known whether the use of these specific 
immunosuppression agents or the total burden of the received 
immunosuppression contribute more to the inadequate im-
mune response to vaccination.
Furthermore, hypogammaglobulinemia, which is often 
observed after transplantation, seemingly plays an important 
role in the decrease of immune response to vaccination. This 
observation was documented in transplant heart, kidney and 
lung recipients and was associated with the development of 
recurrent infections. Indeed, in a study involving patients with 
hypogammaglobulinemia, a protective response to pneumo-
coccal vaccination was absent in 30%, to diphtheria in 15%, 
and to tetanus in 19% of cases. Patients with immunoglobulin 
levels <400 mg/dL had a poorer survival rate and a higher risk 
of invasive infections from cytomegalovirus. Therefore, the 
lack of innate immunity and the impaired antibody related 
response to vaccination may lead to an insufficient immune 
protection after solid organ transplantation.
The production of new memory cells and the survival 
of those cells acquired before transplantation are of critical 
importance for the expression of a capable response to vac-
cination. The effect of therapeutic immunosuppression on 
memory T-cells and on their life expectancy has not been 
fully elucidated. However, there is evidence that the booster 
administration of one or more additional vaccine doses can 
mobilize the immune memory acquired before transplantation 
and support a more effective response than that achieved by 
initial immunization.4
While health care professionals should make every effort 
that applicants to transplantation complete the vaccination 
timetable prior to the procedure, it should be highlighted 
that vaccines containing inactivated strains are generally safe 
also after solid organ transplantation. Particularly where bib-
liographic data regarding efficiency and safety of inactivated 
vaccines in transplant candidates are lacking, the recommenda-
tions of the national immunization advisory committees, de-
signed for the general population, should be strictly followed.
There is no documentation that correlates graft rejection 
clinical episodes and previous vaccination exposure. It is gener-
ally accepted that vaccines containing live strains should not be 
administered after organ transplantation. Even if the optimum 
time for a vaccine administration after organ transplantation 
has not been defined yet, most transplant centres expose trans-
plant recipients to vaccination 3 to 6 months after transplanta-
tion, when the levels of the therapeutic immunosuppression 
have been reached and become constant. Additionally, it is 
recognized that at least 4 weeks should elapse between the 
administration of the vaccine and the evaluation of seroconver-
sion on the basis of the protective titers of antibodies, which 
for every vaccine have been documented in the literature.7
O P t I M A L  t I M e  F O r  I M M U N I Z A t I O N 
P r e -  A N D  P O s t - t r A N s P L A N t A t I O N
Candidates for solid organ transplantation may remain 
in transplant registries for an unpredictable, often long, time 
period. This length of time may be used by clinicians, inter 
alia in order to preserve and enhance, with the appropriate 
vaccinations, the serum levels of various antibodies against a 
wide range of disease-causing microorganisms. Thus, there is 
a rising need to draft future guidelines which will incorporate 
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vaccination in the criteria used for pre-transplant evaluation.8
This proposition is reinforced by the fact that before 
transplantation the antigen-related response to vaccination is 
characterized inadequate in many instances and this response 
evolves even more insufficiently after transplantation.2,9,10 
Thus, given that vaccine immunogenicity is often reduced 
as organ failure deteriorates, candidates for transplanta-
tion should be immunized at the earliest time point possible 
during the natural course of the underlying main disease.7 
Other reasons for the timely immunization of patients before 
transplantation include the fact that vaccines containing live 
viruses, e.g. measles, mumps, rubella, varicella and intranasal 
flu vaccine, are ordinarily avoided after organ transplantation. 
National guidelines of some international organizations head 
towards this direction by recommending that vaccination with 
live strains should precede the inception of any therapeutic 
immunosuppression at least by four weeks and in any case it 
should be avoided for the first two weeks after immunosup-
pression exposure.3
An important question arising in clinical practice concerns 
the optimal time for the continuation and/or completion of 
immunization after solid organ transplantation. Although 
this time frame cannot be definitely identified based on the 
available literature, many transplant centers anticipate at least 
two months after transplantation before proceeding to vaccina-
tions. The rationale behind this is to avoid the contribution 
of the high doses of immunosuppression received by patients, 
which may further blunt immune response to the vaccines.3
It is usual to wait three to six months after transplanta-
tion before the administration of vaccines, once maintenance 
levels of the therapeutic immunosuppression are archived.7 
Exceptions are influenza epidemic cases where the objective 
is to administer the inactivated influenza vaccine as early as 
one month after transplantation.3 Therefore, the standard 
vaccination schedule based on the age of the recipient and 
the one suggested for the immunocompromised hosts, e.g., 
pneumococcal vaccines in adults, should be administered at 
least two to six months after transplantation.3
r I s K  O F  G r A F t  r e J e c t I O N
The unwillingness of the clinicians to allow vaccine admin-
istration in transplant patients stems from a variety of factors, 
including the fear of triggering the mechanisms of allograft 
rejection. This issue was raised in the literature mainly from 
publications of small series of patients and individual case 
reports with scarce documentation. Indeed, in a study where 
two doses of influenza vaccine were administered in heart 
transplant patients, rejection episodes were experienced by 
4 of the 14 heart transplant recipients, but by only one of the 
14 controls (p = 0.326).11
However, almost all large studies, conducted on this topic, 
failed to document an increase in graft rejection or a significant 
clinical dysfunction of the graft after vaccination.12,13 Moreover, 
many recent literature references contain additional documen-
tation for the safety of certain vaccines after transplantation, 
such as the influenza vaccine. Two studies, where 62 and 51 
liver transplant recipients were included, demonstrated the 
effectiveness and safety of the influenza vaccine. At the same 
time they pointed out that vaccination against the influenza 
virus was not associated with allograft rejection or transami-
nase flares in liver transplant recipients.14
In a randomized trial where 58 heart transplant recipients 
were included, at least six months before their enrolment in the 
study, two different but antigenically identical vaccines, which 
differ only for the presence of adjuvants, were administrated. 
Influenza symptoms were observed in 33% and 29% of the 
vaccinated patients, in comparison to 61% of the control 
group. In the same study, four episodes of acute myocardial 
rejection were identified without differences between the 
three study groups.15
In another study, which included 29 vaccinated cardiac 
transplant recipients; vaccination against influenza did not 
alter the percentage of lymphoid subpopulations and did not 
induce the generation of anti-HLA alloantibodies. Response 
to vaccination was detected in 12 of 29 patients and did not 
correlate with rejection history, length of graft survival, or the 
received immunosuppressive therapy. Vaccination did not 
change the frequency of rejection. Flu-like symptoms were 
reported in one patient but the possible association is not 
confirmed microbiologically.16
Another study, which included 3601 heart transplant recipi-
ents from 28 transplant centers, did not detect any variances, 
possibly related to vaccination, in the prevalence or the sea-
sonality of graft rejection. However, it seems that differences 
exist between current recommendations and clinical practice. 
Current practice recommends that all immunosuppressed 
patients should receive vaccination against influenza. In the 
same study, large disparities were observed between vaccina-
tion practices used by different transplant centers. An 89% of 
the institutions administered flu vaccines, with 7 institutions 
requiring adequate range of time between transplantation and 
the introduction of vaccination. More specifically in one centre 
more than three months were required in order to introduce 
vaccination after transplantation, in another more than six 
and in five centers more than 12 months. All 25 centers that 
vaccinated patients used trivalent inactivated vaccines. Three 
centres did not vaccinate their patients due to a supposed as-
sociation of vaccination with an increased allograft rejection. 
There were no significant differences in the total number of re-
jection episodes (0.4% vs 0.3%, p = 0.7), rejection episodes by 
month (January 0.4% vs 0%, p = 0.2; February 0.5% vs 1.5%, 
p = 0.08; March 0.5% vs 0%, p = 0.14), all infections (0.7% 
vs 0.6%, p = 0.6) and viral infections (0.1% vs 0%, p = 0.17) 
between centers that administered flu vaccines and those that 
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did not, respectively. The incidence of the influenza was low 
in both groups.17 Additionally in a recent study where 51.730 
adult kidney transplant recipients were included, vaccination 
against influenza in the first year after transplant was associ-
ated with lower risk of subsequent allograft loss and death.18
Furthermore, in a recent study that included 51,730 adult 
renal transplant recipients, vaccination against influenza con-
ducted during the first year after transplantation was associated 
with lower possibility of subsequent both graft and life loss18.
c O N c L U D I N G  r e M A r K s
Despite a lack of powerful literature data, most vaccines 
are thought to be safe for patients with end-stage organ failure 
or solid organ transplant recipients. The potential benefit of 
achieving immunity against various infectious agents in such a 
vulnerable patient population constitutes a major medical ad-
vantage. Contrariwise, every vaccine that is not administrated 
is by definition 100% ineffective. Therefore, every such patient 
should be encouraged to be vaccinated. Every chance to ac-
cess a vaccination program should be provided to any single 
transplant candidate where solid organ transplantation is the 
only future prospect.
Rejection episodes are not associated in the literature with 
previous vaccination exposure. Furthermore, several viral in-
fections have been reported to trigger rejection. This suggests 
that infectious agents, more than vaccines, are a common cause 
of rejection, and effective immunization may be protective.
The clinicians should aim at full vaccination coverage of 
both the patient and household members of patient’s family 
before transplantation. Vaccination should be carried out as 
soon as possible during the natural history of the underlying 
disease. Finally, special attention should be paid to the vac-
cination of medical practitioners and nursing staff that are in 
close contact with such a vulnerable patient population.
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